Eurofins – Transplant Genomics Announces TRULO Registry Study to Evaluate Long-Term Clinical Outcomes in Patients Monitored with TruGraf® Testing

B2B Training: What’s the Most Effective Way of Learning?

B2B training, which is short for business-to-business training, is a popular and convenient type of training that enables entire companies to train their teams...

AlixPartners Forecasts: Household Products Could Cost U.S. Manufacturers and Consumers 15% More This Year Due to Resin Shortage

While companies can’t control the market forces at play, they can take action to mitigate the risk and impact of supply chain disruption.

Eurofins – Transplant Genomics (“TGI”), a molecular diagnostics company committed to improving organ transplant outcomes with non-invasive serial monitoring guided by genomics, today announced patient enrollment will begin in their TRULO (“TruGraf Long-term clinical Outcomes”) registry study.

TRULO is a prospective, multicenter observational registry study, designed to evaluate post-transplant clinical outcomes in recipients of kidney transplants who are undergoing serial TruGraf testing.  This will be the first study to provide long-term data, beyond 2 years post-transplant, regarding the benefits of non-invasive surveillance of stable kidney transplant recipients to rule out silent subclinical rejection.

The TRULO post-transplant registry, which will be comprised of 2,000 transplant patients from up to 50 transplant centers, incorporates both TruGraf patient monitoring and TRAC™ donor-derived cell-free DNA measurements. This study is unique in that it focuses on patients that are more remote from their transplant and will correlate TruGraf and TRAC monitoring with long term outcomes.  The information from this study has the potential to help improve long term survival of transplanted kidneys.

spot_img

DON'T MISS

Mediclinic Appoints 2 New Independent Non-Executive Directors

Natalia Barsegiyan and Zarina Bassa will bring significant and diverse skills and experience, complementing those of existing Board members. I am confident they will both be great additions to our Board of Directors.”

Asensus Surgical Appoints Two New Board Members

Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™, today announced the expansion of its Board of Directors, appointing...

Our Sister Publication: Biotechnology News Magazine

Subscribe to Medical Device News Magazine here.